Xylocydine is an inhibitor of CDK1/2, suppressing CDK activity in various apoptotic processes; it specifically blocks CDK1 and CDK2 activity with IC50 values of 1.4 nM and 61 nM, respectively; additionally, it downregulates the levels of phosphorylated nucleolin and retinoblastoma protein.